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Abstract Cladribine has been used in the treatment of hairy
cell leukemia for about 30 years. In addition, the number of
indications for the application of 2-CdA is constantly in-
creasing. The treatment with cladribine, of younger persons
and even children, appears to be a major factor stimulating
the more exact recognition of its activities. However, till
now, little has been known about the impact of cladribine on
the reproductive system. The aim of the study was to eval-
uate the immunohistochemical expression of cell prolifera-
tion and apoptosis markers in ovarian surface epithelial
(OSE) cells. In our study, ten rats were placed into two
equal groups. The study group received daily subcutaneous
injections of cladribine in a dose of 0.10 mg/kg of weight/
day for one cycle lasting 7 days. The control group received
only saline injections. The rats were sacrificed 24 h after the
last injection, and their ovaries were extracted. The sections
were immunohistochemically stained with cell proliferation
marker Ki-67 and the apoptosis marker caspase 3. The
expressions of the markers were evaluated using a light
microscope. An analysis was made using an image analysis
system and the CellAD software. The results were then
statistically explored by way of the Mann–Whitney U test.
The proliferative index (Ki-67) of ovarian surface epithelial
cells was significantly lower in the study group than in the
control group (p<0.05). These results suggest that cladri-
bine treatment has a potential to inhibit the OSE cell prolif-
eration in rats. The apoptosis marker demonstrated a
significant increase after the cladribine treatment. These
suggest that cladribine induces apoptosis in OSE cells.
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Introduction
The ovarian surface epithelium (OSE) covers the entire
ovary, separating the peritoneal cavity from the ovarian
stroma while maintaining a constant contact between these
structures. The epithelium rests on the basal membrane,
under which there is a collagenous connective tissue layer,
the tunica albuginea (Auersperg et al. 2001). Just below the
tunica albuginea, in the ovarian cortex, ovarian follicles that
are in various stages of maturity can be found. The devel-
opment stage of a given follicle, connected with the phase of
the menstrual cycle and hormonal level, plays a crucial role
in the structure and functions of the OSE. As the ovaries
prepare to release a mature oocyte, the OSE cells undergo a
gradual degeneration under the influence of different factors
(Murdoch and McDonnel 2002; Slot et al. 2006).
Proteinases (including collagenases) cause the degradation
of connective tissue elements while the OSE cells undergo
apoptosis allowing the release of the oocyte from the ovary.
The site of rupture (wound) of the layer covering the ovary
after ovulation is then restored by proliferating OSE cells
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that migrate to the edges of the wound (Gava et al. 2008;
Murdoch and McDonnel 2002).
It has also been demonstrated that OSE cells synthesize
various substances present in the extracellular matrix and
also exhibit contractile activity (Auersperg et al. 1991). It is
believed that the variation of the epithelial cells is not firmly
determined, and they may constitute precursors, not only for
new OSE cells, but also for other cell types, such as the
ovarian stromal cells, as well as the epithelial cells of the
oviduct or endometrium. This type of conversion protects
against the formation of aggregates of epithelial cells in
unusual sites, e.g., the interior of the ovary. However, at
the same time, this conversion favours the circumvention of
the mechanisms that control the proliferation and differen-
tiation of OSE cells, which leads to the formation of many
types of neoplasms derived from the ovary (Singavarapu et
al. 2010). Data show that 90 % of human ovarian malignant
neoplasms are derived from the OSE (Auersperg et al.
2001). The proliferation of OSE cells is increased after each
ovulation in order to repair the interrupted continuity of the
epithelium. Different factors can disrupt this process, lead-
ing to changes within the tunics covering the ovary. These
factors include inflammation in the genital tract, the activity
of reactive oxidants, hormonal stimulation of ovulation, and
also the use of various therapeutic agents acting systemical-
ly. Substances that have been reported to affect both the
course of proliferation and other processes related to the cell
cycle include immunosuppressive and anticancer drugs,
among these, steroids, cytotoxic drugs, and monoclonal
antibodies. So far, there has been little data on the detailed
effects of the drugs of this kind on the OSE cells (Perez et al.
1993).
The purine nucleoside analogues (PNA), which include
cladribine, constitute a group of cytostatic drugs, which
result in the induction of apoptosis in both proliferating cells
and those remaining at rest. The mechanism of PNA is
multidirectional and is still not fully discovered. PNA exhib-
its the highest activity in lymphoid cells due to the favour-
able concentrations of active enzymes present in such cells.
Active PNA metabolites cause a number of changes in the
cell, leading to its destruction (Johnston 2011; Robak et al.
2009). The effect of PNA on cells is partially dependent on
the p53 protein, and mutations within the gene of the p53
protein may weaken or remove the impact of PNA (Schlette
et al. 2009). However, other ways of activating PNA apo-
ptosis that are independent of the p53 protein in the cells
have been described (Robak et al. 2009; Johnston 2011).
There are many known side effects induced by cladri-
bine. These are connected mainly with the suppressive
effects of 2-CdA on the bone marrow. The consequences
resulting from myelosuppression include inter alia, leuko-
penia, thrombocytopenia, and anemia. The side effects of
cladribine also include bacterial, viral, and fungal infections;
disorders of the nervous system (headaches, dizziness, in-
somnia, anxiety, peripheral neuropathy), cardiac insufficien-
cy, nephropathy, disorders of the gastrointestinal tract
(nausea, vomiting, abdominal pain), musculoskeletal disor-
ders, local skin reactions, teratogenicity and infertility, and
also secondary malignancies, such as, acute myeloid leuke-
mia (AML), non-Hodgkin lymphoma (NHL) (Chubar and
Bennett 2003; Rossini et al. 2004; Hassan et al. 2004;
Marczak et al. 2004; Saven et al. 1998; Tawfik and Nasr
2011).
The effect of PNA on the genital tract has not yet been
accurately described. This is probably because these have
been mostly administered for the treatment of hairy cell
leukemia, which occurs mainly in older people. However,
currently, PNA administration has become a useful tool in
treating young persons and even children. Indeed, positive
effects of cladribine in the treatment of chronic lymphocytic
leukemia have been described (Chow et al. 2000), as its
efficacy in treating NHL [Chow et al. 2000], mantle cell
lymphoma (Inwards et al. 2008), AML (Wierzbowska et al.
2008), myelodysplastic syndromes (Laurencet et al. 1997),
chronic myeloid leukemia (Martinelli et al. 1996),
Waldenström macroglobulinemia (Rourke et al. 2010), his-
tiocytosis, also in children (Mottl et al. 2006), astrocytomas
(Ceruti et al. 2000, Ceruti et al. 2003), multiple sclerosis
(Hartung 2009; Leist and Weissert 2011; Vosoughi and
Freedman 2010), mast cell disease (Aichberger et al.
2008), psoriasis, including psoriatic arthritis (Eibschutz et
al. 1995), systemic lupus erythematosus (Bernknopf et al.
2011), angioedema, and anaphylaxis (Dutta et al. 2002).
In this research, we examined the effects of cladribine on
the OSE cells of female Wistar rats. In so doing, the expres-
sion of caspase 3 and the nuclear antigen Ki-67 in the OSE
cells of rats subjected to cladribine to assess apoptosis and
proliferation in these cells has been evaluated.
Materials and methods
Experimental model
White female Wistar rats were used for the study. The rats
were 3 to 4-month-old females with an average body weight
of 275 g. Cladribine was applied subcutaneously, inter-
changeably in the right and left side skinfolds at the height
of the lumbar spine (the study was approved by the Local
Bioethics Commission of Medical University in Lublin
number 126/2001). During the experiment, the animals were
housed in cages with a surface area of 0.5 m2, with a
preserved circadian cycle (12-hday, 12-h night), air temper-
ature around 21 °C, and relative humidity around 60 %. The
rats received standard LSM feed and water without limita-
tions. Before starting the experiment, a cytological smear of
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females was analyzed to determine the phase of the estrous
cycle of the studied females. In all the studied females, the
estrous cycle lasted 4 days and consisted of four phases:
proestrus, estrus, metestrus, diestrus. On the first day of the
fourth cycle, drug administration was begun.
Research groups
The animals were randomly placed into two groups: one
control group (K) and one study group (A), each of which
consisted of five individuals. The animals in the study group
were administered the drug at a dose of 0.10 mg/kg body
weight/24 h, for 7 consecutive days, at exactly the same time.
The dose used corresponded to the therapeutic dose used in
the treatment of proliferative disorders of the lymphatic sys-
tem in humans. The control group animals received only food
and water without limitations. In order to introduce a stress-
inducing factor as to that of the study group, rats in the control
group were administered physiological saline subcutaneously
in a volume corresponding to the amount of drug administered
to rats in the study group. Decapitation of the animals of both
groups was conducted 24 h after the last injection, i.e., on the
fourth day of the cycle (the final stage of diestrus). Their
ovaries were then taken for histomorphological and immuno-
histochemical tests.
Histological tests (H&E staining, immunohistochemical
tests)
After fixing the material in 10 % formalin, the organs were
embedded in paraffin blocks. The material was then tailored
into sections 5-μm thick. The histomorphological evalua-
tion of tissues stained with hematoxylin and eosin (H&E)
was performed with the use of a light microscope, at×400
and×1,000 magnification. Immunohistochemical tests were
then done using antibodies that were produced by Sigma
directed against the antigen Ki-67 and caspase 3. The expo-
sure of the antigenic sites was performed thermally by
incubation in citrate buffer solution with pH06, in a micro-
wave oven at 800 W, for three cycles lasting 5 min each. To
inhibit endogenous peroxidase activity, 0.3 % perhydrol
(H202) in methanol was used. Normal Serum was also used
to block the nonspecific bindings of antigen. The material
was incubated in a primary antibody diluted as recommen-
ded by the manufacturer (1:150 for Ki-67, 1:100 for caspase
3) overnight at 4 °C. To visualize the reaction, diaminoben-
zidine solution and hematoxylin coloration were used. In the
negative control, experiments were conducted in a similar
manner but omitted the specific primary antibody. The ma-
terial was evaluated with the use of a light microscope at×
400 magnification.
Subsequently, randomly selected 15 corpora lutea in the
process of repair from the animals of study group and the
control group underwent an analysis of the expression of
individual proteins (on average, 20–75 cells in each corpus
luteum). OSE cells with positive expression were counted.
After this, the percentage of Ki-67- and caspase 3-positive
cells was calculated (the number of protein-positive cells
divided by the total number of cells counted multiplied by
100). Moreover, the intensity of expression of individual
proteins of OSE cells was compared. The intensity was
graded as low (+), intermediate (++) and high (+++), by
using the BX4 image analysis system manufactured by
Olympus, with a DP 25 digital camera and the Cell D
software. In addition, the percentage of cells of the given
intensity expression in each tested corpus luteum was cal-
culated. These values were expressed as a mean ± standard
deviation. The obtained tests results were subjected to sta-
tistical analysis with the use of the Statistica 10.0 software.
The chi-square (χ2) test was applied to compare the mean of
Ki-67 and caspase 3 indicating positive and negative cells in
both groups. A statistical analysis of the intensity of protein
expression in both groups was performed with the use of the
Mann–Whitney U test. In this regard, a probability (p) value
less than 0.05 was considered statistically significant.
Results
The histomorphological assessment of ovarian surface
epithelium in H&E staining
OSE cells of the analyzed groups of animals, in the histo-
morphological study, showed no discernible pathological
changes under the light microscope at×400 magnification
(Figs. l and 2). The epithelium located on the newly formed
corpora lutea was cuboidal and fragmentarily simple squa-
mous. Cell nuclei showed no abnormalities within their
structure. The basal membrane was also well preserved.
The analyzed OSE cells covered the newly formed corpora
lutea. Vacuoles were commonly present, particularly in the
Fig. l Ovarian surface epithelium of the study group (A). H&E stain-
ing. Magnification × 400
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cells in the center of these large corpora lutea. Fibrous tissue
formation was seen in what was previously the central,
fluid-filled cavity.
Immunohistochemical evaluation of Ki-67 and caspase 3
expressions in OSE cells
The expression of tested proteins has shown statistically sig-
nificant differences among analyzed groups (Figs. 3 and 4).
The existence of positive expression of the nuclear antigen Ki-
67 in OSE cells was observed to be definitely rare in the study
group, as compared to the control group (p<0.0001 in the χ2
test). A positive expression of caspase 3 was statistically more
frequently observed in the study group, as compared to the
control group (p<0.0001 in the χ2 test). The average percent-
age of cells with positive expression of proteins tested is given
in Table 1.
In addition, the intensity of positive immunoprecipitators
of the antigen Ki-67 was much stronger in the OSE cells of
animals from the control group (Figs. 5 and 6). A statisti-
cally significant difference among the groups was not
observed only in respect of the frequency of the low inten-
sity of the antigen Ki-67 evaluated as 1 (+) (Fig. 7; Table 2).
The intensity of observed expression of caspase 3 in the
OSE cells of the animals from the study group (Fig. 8) was
much stronger than in the control group (Fig. 9). In this
regard, the differences in the intensity of expression depend-
ing on the research group were statistically significant
(Fig. 7; Table 2).
Discussion
Cladribine (2-chlorodeoxyadenosine, 2-CdA) is a synthetic
derivative of deoxyadenosine (dA), and belongs to the
group of purine nucleoside analogues (PNA). Except for
cladribine, the oldest representatives of this group of med-
icaments are such substances as fludarabin (FA, 2-fluoro-9-
β-D-arabinosyl-2-fluoroadenine, F-ara-A) and pentostatin
(2´-deoxyformacine). In the 1980s, these medicaments were
admitted by the American Food and Drug Administration
for the treatment of neoplasms of the hematopoietic system
(Robak et al. 2009).
Some new medicaments of this group have become
known, such as clofarabine (2-chloro-9-(2´-fluoro-2´-deox-
yarabinofuranosilo)adenine, CAFdA), nelarabine (6-
metoxy-9-(D-urubinofurunosilo)guanine), and forodesine
(immunocyline H, BCX-1777, 7-(3,4-dihydroxy-5-hydrozy-
methylpyrrolidine-2-yl)-3,5-dihydro-pyrrolo[3,2d]pyrimi-
din-4-on). These have been found applicable for treatments
of disorders resistant to the current therapy (Korycka et al.
2007; Korycka 2008; Robak et al. 2009).
Compounds of this group are of similar chemical struc-
ture based on their nucleoside ring. Particles of purine
nucleosides were modified in order to change their pharma-
cological properties and, most of all, in order to increase
Fig. 2 Ovarian surface epithelium of the control group (K). H&E
staining. Magnification × 400
Fig. 3 Percentage of positive
Ki-67 OSE cells associated with
the newly formed corpora lutea
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their resistance to enzymes responsible for their decompo-
sition, such as adenosine deaminase (ADA).
Cladribine was synthesised in the Scripps Research
Institute in the 1970's. Through the substitution of its hy-
drogen atom, with a chlorine atom in position 2 of the
deoxyadenosine ring, cladribine is resistant to ADA activity.
It may be applied in the form of intravenous infusion,
intracutaneous injection or orally taken pills (Tawfik and
Nasr 2011). 2-CdA penetrates the cerebrospinal fluid, reach-
ing a concentration of nearly 25 % in the serum. Cladribine
is transported to the nuclei of cells by means of nucleoside
transporters (Leist and Weissert 2011). In the cell, it is also
subordinated to phosphorylation to 2-CdATP being an ac-
tive form of cladribine. It is extracted from the organism
through the kidneys in an unchanged form (21–35 % of a
dose) and in the form of a hydrolysed metabolite—2-chlor-
oadenine which is characterised also by apoptosis induction,
but in definitely higher concentrations than 2-CdA.
The presence of active metabolites of purine nucleoside
analogues in the cell induces numerous enzymatic and struc-
tural changes that disturb the balance among damaging factors
and reparatory mechanisms, resulting in the cell’s death. The
activity of PNA is mostly linked with the inhibition of the
synthesis of deoxynucleotides which play an important role in
DNA replication and repair. Moreover, they inhibit the activ-
ity of ribonucleotide reductase, which is an enzyme condition-
ing the promptness of diphosphodeoxyribonucleotides
(dNDP). The inhibited activity of dNDP disturbs the balance
within the nucleoside triphosphates, which activates endonu-
cleases, resulting in a rupture in one of both DNA strands
(Johnston 2011; Robak et al. 2009). DNA damages then
initiate the reparatorymechanisms and activates the polytrans-
ferase enzyme. Induction of reparatory processes results in
depletion of NAD energetic reserves, the inhibition of ATP
synthesis, a disturbance of all energetic processes and finally,
cell death. Cladribine phosphate also acts as a DNA synthesis
inhibitor and results in the inhibition of the cell cycle (Leist
and Weissert 2011).
The presence of intracellular changes is a signal for
increased expression of regulatory protein p53. This p53
protein may block the cell cycle at control points of cell
cycleG1/S or G2/M, in order to initiate reparatory mecha-
nisms in a cell. If irreparable damages occur, p53 protein
directs a cell to follow the apoptosis pathway (Johnston
2011; Klöpfer et al. 2004; Korycka 2008). The typical
course of apoptosis is linked to the activation of caspases.
The initiatory caspase 9 plays a crucial role in the endoge-
nous apoptosis pathway, whereas the key stage in the exter-
nal pathway is the activation of the death receptor and
caspase 8.
The mechanism of apoptosis induction through cladri-
bine is the subject of many studies. Numerous publications
show the increased activity of caspase 9 (Bastin-Coyette et
al. 2008; Conrad et al. 2008; Klöpfer et al. 2004). Individual
data also reveal the activation of the FAS receptor and
caspase 8 through 2-CdA (Nomura et al. 2000). Moreover,
in astrocytoma cells incubated in a cladribine-rich environ-
ment, increased expression of caspase 2 was evidenced, that
an atypical mechanism may activate the internal apoptosis
pathway (Ceruti et al. 2003). Cladribine may also directly
Fig. 4 Percentage of positive
caspase 3 OSE cells associated
with the newly formed corpora
lutea
Table 1 Percentage of OSE cells with positive expression of antigen Ki-67 and caspase 3
Protein Group A (study) Group K (control)
Number Mean Min Max Standard deviation Number Mean Min Max Standard deviation
Ki-67 15 33.40 % 22.00 % 44.00 % 7.16 % 15 76.60 % 63.00 % 90.00 % 8.48 %
Casp3 15 73.17 % 54.34 % 84.00 % 9.60 % 15 32.27 % 20.68 % 47.29 % 8.35 %
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activate the apoptotic protease activating factor 1 or induce
increased permeability of the mitochondrial membranes for
cytochrome c through a caspase-independent mechanism.
The intracellular concentration of calcium ions probably
also plays an important role in cladribine-induced apoptosis
(Conrad et al. 2008). Moreover, the activation of p38
nitrogen-activated protein kinase (MAPK p38) and extracel-
lular signal-regulated kinase 1 and 2 (ERK1/2) are other
options to trigger cell death through 2-CdA (Conrad et al.
2008; Smal et al. 2007).
The execution stage relying on the disintegration of the
cell and resulting in apoptotic bodies occurs after the initi-
ation of apoptosis. The effector caspases play an important
role within this stage, and caspase 3 is one of the most
significant executive caspases of the apoptosis process. It
is responsible for the proteolysis of intracellular proteins and
for morphological changes characteristic of apoptosis
(Korzeniewska-Dyl 2007). The measurement of its activity
serves for the assessment of the intensity of this process in
cells (Chmielewski et al. 2008).
In our study, we have assessed the expression of caspase
3 in OSE cells in female rats treated with cladribine. The
results of this analysis demonstrate that 2-CdA induces a
cytotoxic effect upon cells of this epithelium. Furthermore,
the statistically significant growth in expression of caspase 3
in OSE cells in the study group, as compared to the control
group, is evidence for the intensification of the apoptosis
process in cells that are influenced by cladribine.
So far, the inductive activity of 2-CdA on programmed
cell death in the lymphatic system has been confirmed.
Individual publications concern the damage of skin cells
and the mucous membrane that was brought about by cla-
dribine (Chubar and Bennett 2003; Rossini et al. 2004).
Moreover, several publications also described the cytotoxic
activity of cladribine on stem cells (Chow et al. 2002; Lech-
Marańda et al. 2000; Petzer et al. 1991). In a study on the
impact of cytostatic drugs on cells at various stages of
maturity, Chow et al. showed that cladribine induces apo-
ptosis in CD34+/CD38+ progenitor cells (Chow et al. 2002).
Lech-Marańda et al. observed the inhibition of granulocyte–
macrophage progenitor cell growth, and Petzer et al. ob-
served the inhibition of T lymphocyte colony forming cells
subject to cladribine (Lech-Marańda et al. 2000; Petzer et al.
1991).
Cells of a stem cell nature are described among the cells
forming the ovarian surface epithelium (Chang et al. 2008).
A large amount of data suggests the potential of these cells
to differentiate into various forms of progeny cells, such as,
ovarian stromal cells, germ cells, or even oocyte-like cells
(Nishida and Nishida 2006; Virant-Klun et al. 2011).
Disturbances in the proliferation and maturation of these
cells are probably linked with the development of ovarian
cancer (Chang et al. 2008; Nishida and Nishida 2006).
Researchers have shown that the application of gonadotro-
pins to stimulate ovulation results in changes of proliferation
activity of these cells. The majority of data reveals that
gonadotropins, such as, human chorionic gonadotropin,
pregnant mare’s serum gonadotropin, and 17β-estradiol ac-
celerate the proliferation of ovarian cells, including OSE
cells (Stewart et al. 2004; Singavarapu et al. 2010). Also,
surgically induced injury or ovulation-induced rupture of
Fig. 5 Expression Ki-67 in OSE cells study group (A). Magnification
× 400
Fig. 6 Expression Ki-67 in OSE cells control group (K). Magnifica-
tion × 400
Fig. 7 Expression of antigen Ki-67 and caspase 3 of defined intensity
in particular research groups. Statistically significant differences in the
intensity of protein expression are visible, except for the low expres-
sion of the antigen Ki-67 (Ki-67*)
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the ovarian surface increase OSE cells proliferation rate
(Stewart et al. 2004). Accelerated proliferation is often
linked with the occurrence of irregularities in the genetic
material of progeny cells, as well as the inhibition of repair
mechanisms. The proliferation of pathologically changed
OSE cells induces the development of inclusion cysts and
mucous membrane dysplasia, which are potential preneo-
plastic features (Corakci et al. 2005; Chene et al. 2012).
These data explain the signalled increase in the risk of
development of ovarian cancer among persons subject to
ovulation induction as well as among women having early
menarche and late menopause or nulliparous (Corakci et al.
2005; Gava et al. 2008; King and Burdette 2011).
Disturbances in the proliferation process that are linked with
ovarian stimulation are also associated with the occurrence
of defective embryos and miscarriages in the blastocyst
period (Liang et al. 2009).
In our study, we have assessed the impact of cladribine
on the proliferation of OSE cells, by way of evaluating the
expression of Ki-67 antigen in the ovaries of female rats
subject to the activity of 2-CdA. The Ki-67 nuclear antigen
is the basic marker of cell proliferation (Gerdes et al. 1984).
This protein is present in the nucleus, and also in chromo-
somes during cell division. The positive expression of this
antigen is present in cells at the S, G2, and M stages of the
cell cycle, and in G1 after mitosis. The lack of Ki-67 antigen
expression is observed only in quiescent cells at G0 stage
(Gerdes et al. 1984; Muskhelishvili et al. 2003).
A significantly lower intensity of expression of Ki-67
antigen, as compared to the control group, was observed in
OSE cells of ovaries sampled from animals subject to cla-
dribine injections (group A). The percentage of Ki-67 pos-
itive OSE cells was definitely higher in the animal tissue of
the control group than in ovaries from the animals in the
study group.
The inhibition of cell growth and proliferation is one of
cladribine’s activity mechanisms described that was con-
firmed in previous studies of lymphatic cells (Lech-
Marańda et al. 2000; Spurgeon et al. 2009). The changes
in OSE cells proliferation activity observed in our studies
may suggest that cladribine has a similar impact upon ovary
epithelium cells.
The inhibition of the proliferation activity of cells facil-
itates the activation of repair mechanisms, the aim of which
Table 2 Expression intensity of Ki-67 and caspase 3 in OSE cells of the study (A) and control (K) group
Expression
intensity
Group K (control) Group A (study) Statistically significant (p),
Mann–Whitney U test
Number Mean Min Max Standard
deviation
Number Mean Min Max Standard
deviation
Ki-67 (+) 15 17.45 % 8.93 % 25.93 % 5.38 % 15 17.16 % 10.53 % 30.56 % 5.89 % 0.708923
Ki-67 (++) 15 32.64 % 20.00 % 46.34 % 8.02 % 15 9.90 % 5.36 % 16.22 % 2.96 % 0.000003
Ki-67 (+++) 15 26.43 % 18.52 % 37.50 % 5.92 % 15 5.61 % 1.79 % 10.64 % 2.47 % 0.000003
Casp3 (+) 15 16.77 % 5.56 % 32.43 % 6.81 % 15 33.78 % 13.21 % 50.98 % 10.77 % 0.000223
Casp3 (++) 15 9.64 % 6.25 % 13.89 % 2.34 % 15 22.83 % 12.07 % 47.17 % 8.90 % 0.000007
Casp3 (++) 15 5.86 % 3.13 % 10.26 % 2.03 % 15 16.60 % 9.38 % 22.22 % 3.57 % 0.000004
Fig. 8 Expression of caspase 3 in OSE cells study group (A). Magni-
fication × 400





















Fig. 9 Expression of caspase 3 in OSE cells control group (K).
Magnification × 400
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is to repair damages in the genetic material of a cell that
resulted from various factors (Sznarkowska et al. 2010). As
it was shown in many studies, cladribine is one of the factors
inhibiting the cell cycle at control point G1/S (Galmarini et
al. 2003). Retention of cells between these phases is prob-
ably dependent on an efficiently operating p53 protein in
cells. This protein is responsible for inter alia, cell prolifer-
ation, ageing, and death (Sznarkowska et al. 2010). In
another study, we have shown an increase in p53 protein
expression in OSE cells of animals subject to cladribine.
These results may indicate the initiation of repair mecha-
nisms in these cells. The repair of intracellular damages
caused by cladribine requires time. This is because some
cells undergo apoptosis, which is indicated by a higher
caspase 3 percentage in the group receiving cladribine.
Only properly repaired stem OSE cells may be the source
of intact and mature OSE cells.
The obtained data confirm the claims that cladribine can
be teratogenic and suggest its adverse influence upon the
female reproductive system (Wubah et al. 1996; 2001).
However, the obtained data need to be expanded, especially
with studies on humans, in order to assess the impact of
cladribine upon the reproductive function of females and
males. Specific information will facilitate providing recom-
mendations on the application of substances protecting the
reproductive organs against the harmful activity of cytostat-
ic drugs and ascertaining the safe period of time between the
completion of chemotherapy and procreation. These recom-
mendations appear particularly important due to the increas-
ingly broad application of PNA in medicine.
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